EB Research Partnership
  • Epidermolysis Bullosa
    • What is EB?
    • Life with EB
    • Resources
  • Research
    • Our Impact
    • Scientific Advisory Board
    • Clinical Trials
    • Community Council
    • Apply for a Grant
  • Get Involved
    • Donate
    • Sponsor
    • EB Active
    • Events >
      • Venture Into Cures
    • The Effect
    • Shop
    • Accelerator Fund
  • Media
    • Press
    • Videos
  • About Us
    • Our Mission
    • Financials
    • Venture Philanthropy
    • Supporter Spotlight
    • Leadership >
      • Board of Directors
      • Staff
      • Founders
  • Donate

Clinical Trials

Several clinical trials are recruiting and/or underway. We have listed some below, but you can see a complete list of clinical trials on clinicaltrials.gov by clicking the button.
Visit clinicaltrials.gov
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
Picture
​Researchers find that a gel tested in patients with a life-threatening blistering skin disease helps wounds heal. The gel — the first topical gene therapy — awaits FDA approval.
READ US NEWS ARTICLE
READ LIVE SCIENCE ARTICLE
READ STANFORD ARTICLE

VIITAL Study: Pivotal Phase 3 Clinical Trial of EB-101 for RDEB
Picture
Investigators at Stanford University and the University of Massachusetts Medical School are currently enrolling up to 15 RDEB patients age 6 or older for the VIITAL™ study, evaluating the safety and efficacy of EB-101 for treatment of large, chronic wounds. Additional study centers are expected to begin enrolling patients in Spring/Summer of 2020.  Learn more at the links below or contact Abeona at EB@abeonatherapeutics.com or contact the study sites directly:

Stanford University

Irene Bailey
baileyhi@stanford.edu

University of Massachusetts Medical School
Dr. Karen Wiss
DermResearch@umassmed.edu
View on clinicaltrials.gov
view on med.stanford.edu
EB-101 Fact Sheet

DeFi-RDEB Phase 3 Clinical Trial of FCX-007 for RDEB
 
Picture
Picture
Castle Creek Biosciences has initiated the DeFi-RDEB Study, a Phase 3 Clinical Trial of FCX-007 (also known as D-Fi) , their gene therapy for treatment of RDEB. Patients with RDEB lack collagen VII. This therapy involves taking cells from a patient and genetically modifying them to express collagen VII protein. These corrected cells are then injected intradermally back into the patient. FCX-007 has received several designations from the US Food & Drug Administration, including Orphan Drug, Rare Pediatric Disease, Fast Track, and RMAT.

This study is currently recruiting patients at Stanford University in Stanford, CA, Dell Children’s Medical Group in Austin, TX, Children’s Hospital Colorado in Aurora, CO, Solutions Through Advanced Research in Jacksonville, FL, and Mayo Clinic in Rochester, MN.
View on clinicaltrials.gov
More Info on DeFi-RDEB.com

Phase 1/2 Trial of PTR-01 in Adult Patients With RDEB
Picture
Phoenix Tissue Repair is currently recruiting adults with RDEB for their Phase 1/2 trial of PTR-01, a protein replacement therapy that uses recombinant type VII collagen, to assess the therapy's safety and efficacy. Preclinical studies of PTR-01 have demonstrated anchoring fibril formation and improved survival in RDEB models. The US FDA and European EMA have gratned Orphan Drug Designation to this therapy. The 3 sites include Stanford University, Children's Hospital Colorado, and Thomas Jefferson University.
Interview with CMO
Information from PTR
View on clinicaltrials.gov

A Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
 
Picture
​Stanford is recruiting individuals with EB aged 13 and above to test the safety and efficacy of Serlopitant in reducing itch. This drug works by inhibiting the neurokinin-1 receptor. In EB patients, itching leads to increased disease severity by causing individuals to scratch and create new wounds.
View on clinicaltrials.gov
Information from Stanford

EASE Study: Pivotal Phae 3 Study of FILSUVEZ®
 
Picture
Amryt Pharma has completed the EASE Study, a global Phase 3 Clinical Trial of the topical gel FILSUVEZ® (previously Oleogel-S10 or AP101), to investigate its safety and efficacy in the treatment of EB wounds in patients with Dystrophic EB, Junctional EB, and Kindler Syndrome. In late 2020, Amryt announced positive results from the Phase 3 study and expects to file an New Drug Application with the FDA in 2021. 
View on clinicaltrials.gov
Read Press Release

USC's Gentamicin Studies
Researchers at USC are studying Gentamicin as a therapy for RDEB adn JEB causes by nonsense mutations. Gentamicin is an aminoglycoside antibiotic which can override nonsense mutations in DNA sequences, allowing full length, functional proteins to form. USC is currently recruiting for all 3 trials below.
Picture
Intravenous Gentamicin Therapy for RDEB
Individuals with a nonsense mutation in the Collagen VII gene may be eligibel for this Phase 1/2 Clinical Trial. Previous studies of topical and intradermal gentamicin have shown positive results in Recessive Dystrophic EB patients, so the researchers are testing if intravenous intervention will provide a systemic solution.
View on clinicaltrials.gov
Gentamicin for JEB
Individuals with nonsense mutations in the LAMB3 gene may be eligible for this clinical trial. 80% of Herlitz JEB (H-JEB) have LAMB3 mutations, 95% of which are nonsense mutations. The investigators have already demonstrated that Gentamicin induced nonsense readthrough, producing full length protein, in several nonsense mutations. In this trial, Gentamicin will be delivered to 3 subjects intravenously and 3 subjects topically. 
View on clinicaltrials.gov
Optimizing IV Gentamicin in JEB
Individuals with nonsense mutations in the LAMB3 gene or LAM3A gene may be eligible for this clinical trial. The investigators aim to optimize the intravenous gentamicin regimen for enhanced therapeutic results. The study will measure expression of Lamnin 332 in the skin as well as the safety of the therapy.
View on clinicaltrials.gov

Stem Cell Transplant
Picture
Researchers at the University of Minnesota are seeking participants with severe EB to determine if stem cell transplantation of bone marrow or umbilical cord blood from a healthy donor will correct protein deficiencies and reduce skin fragility.
View on clinicaltrials.gov

EB Research Partnership

244 Madison Ave Ste 104
New York, NY 10016 
info@ebresearch.org
646-844-0902
Careers

Contact Us
​

Donor Privacy Policy
Donate

​Our Mission

​
Shop

Press
Picture

COPYRIGHT @2022 EB RESEARCH PARTNERSHIP. ALL RIGHTS RESERVED. EB RESEARCH PARTNERSHIP IS A 501(C)(3) NON PROFIT.

  • Epidermolysis Bullosa
    • What is EB?
    • Life with EB
    • Resources
  • Research
    • Our Impact
    • Scientific Advisory Board
    • Clinical Trials
    • Community Council
    • Apply for a Grant
  • Get Involved
    • Donate
    • Sponsor
    • EB Active
    • Events >
      • Venture Into Cures
    • The Effect
    • Shop
    • Accelerator Fund
  • Media
    • Press
    • Videos
  • About Us
    • Our Mission
    • Financials
    • Venture Philanthropy
    • Supporter Spotlight
    • Leadership >
      • Board of Directors
      • Staff
      • Founders
  • Donate